Evaluation of the long-term safety and tolerability of oral atogepant 60 mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the advance trial

被引：0
|
作者：
Klein, B. [1 ]
Miceli, R. [2 ]
Severt, L. [2 ]
McAllister, P. [3 ]
Mechtler, L. [4 ]
McVige, J. [4 ]
Diamond, M. [5 ]
Marmura, M. J. [6 ]
Guo, H. [2 ]
Finnegan, M. [2 ]
Trugman, J. M. [2 ]
机构：
[1] Abington Neurol Associates Ltd, Abington, PA USA
[2] AbbVie, Madison, NJ USA
[3] New England Inst Neurol & Headache, Stamford, CT USA
[4] DENT Neurol Inst, Amherst, NY USA
[5] Diamond Headache Clin Ltd, Chicago, IL USA
[6] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
AL077
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study
    Sakai, Fumihiko
    Suzuki, Norihiro
    Ning, Xiaoping
    Ishida, Miki
    Usuki, Chiharu
    Iba, Katsuhiro
    Isogai, Yuki
    Koga, Nobuyuki
    DRUG SAFETY, 2021, 44 (12) : 1355 - 1364
  • [22] LONG-TERM SAFETY AND TOLERABILITY OF ONABOTULINUMTOXINA TREATMENT IN CHRONIC MIGRAINE PATIENTS TAKING ORAL PREVENTIVE MEDICATIONS: COMPEL ANALYSIS BY TREATMENT CYCLE
    Winner, P. K.
    Blumenfeld, A. M.
    Eross, E. J.
    Orejudos, A.
    Adams, A. Manack
    Brin, M. F.
    CEPHALALGIA, 2018, 38 : 75 - 76
  • [23] Effect of long-term preventive treatment with oral rimegepant 75 mg on migraine-related disability: A 52-week, open-label extension study
    Lipton, R. B.
    McAllister, P.
    Turner, I. M.
    Schim, J. D.
    Litalien, G. J.
    Jensen, C. M.
    Thiry, A. C.
    Kamen, L.
    Coric, V
    Croop, R.
    HEADACHE, 2022, 62 : 136 - 137
  • [24] Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis
    DeCuyper, C
    BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 (01) : 156 - 157
  • [25] Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, (vol 60, pg 141, 2020)
    Ailani, J.
    Lipton, R. B.
    Hutchinson, S.
    Knievel, K.
    Lu, K.
    Butler, M.
    Yu, S. Y.
    Finnegan, M.
    Severt, L.
    Trugman, J. M.
    HEADACHE, 2021, 61 (06): : 978 - 981
  • [26] Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
    Staskin, David
    Frankel, Jeffrey
    Varano, Susann
    Shortino, Denise
    Jankowich, Rachael
    Mudd, Paul N., Jr.
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1421 - 1428
  • [27] Long-term clinical trial safety experience with adalimumab 40 mg every other week for treatment of moderate to severe psoriasis
    Tyring, Stephen
    Frankel, Ellen
    Rozzo, Stephen
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB131 - AB131
  • [28] Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR) REPLY
    不详
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1429 - 1429
  • [29] Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR) COMMENT
    Chapple, C. R.
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1428 - 1429
  • [30] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
    Croop, R.
    Madonia, J.
    Hould, J.
    Mosher, L.
    Lovegren, M.
    Coric, V.
    Lipton, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
12345